Clinical Lymphoma Myeloma & Leukemia

Papers
(The TQCC of Clinical Lymphoma Myeloma & Leukemia is 0. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)
ArticleCitations
OA-27 Para-Medullary (PMD) and Extra-Medullary (EMD) Myeloma Demonstrate Increased Copy Number Aberration, Mutational Burden, Structural Variants and Genomic Complexity Compared to Marrow-Based Myelom66
P-012 Real-World Safety and Early Efficacy of Talquetamab in Patients with Heavily-Pretreated Relapsed/Refractory Multiple Myeloma46
P-113 An Artificial Intelligence-Based 3D-Segmentation Assessment of Sarcopenia Utilizing Whole-Body Computed Tomography in Patients With Multiple Myeloma41
P-068 Developing Novel DKK1-A2 CAR-T Cell Therapy for Myeloma and Other Hematologic Malignancies41
P-112 Fall Risk Assessment and Fall Prevention in Patients With Multiple Myeloma: First Results of the MYFALL-Trial34
P-186 Identifying a New Risk-Stratification Strategy by Including Single-Cell Biomarkers in Multiple Myeloma33
P-154 Multidisciplinary, Patient-Centric Bone Disease Management in Multiple Myeloma – a Single-Centre Experience33
P-330 Stem Cell Mobilization Strategy With Pegilgrastim for Stem Cell Transplantation for Multiple Myeloma: A Direct Cost Comparison32
P-202 Risk Factors Predicting Early Relapse for Newly Diagnosed Multiple Myeloma Patients Treated with Front-Line VRD Regimen32
P-314 Daratumumab for Refractory Proliferative Glomerulonephritis With Monoclonal Immunoglobulin G Deposits and Severe Chronic Kidney Disease29
P-342 Impact of Achieving <VGPR With Dara-RVD Induction Therapy in Newly Diagnosed Multiple Myeloma (NDMM) Patients28
P-232 Comprehensive Genomic Sequencing Predicts Sub-Optimal Response to Bispecific Antibodies (BsAb) and Chimeric Antigen Receptor T Cells (CAR-T) in Multiple Myeloma (MM)28
P-309 Diagnostic Challenges in Systemic Amyloidosis: Exploring the Impact of Mass Spectrometry in a Middle-Income Country Cohort28
MM-508 Belantamab Mafodotin for Relapsed or Refractory Multiple Myeloma: A Real-World Observational Study Update26
Poster: CT-329 CD19-Directed Chimeric Antigen Receptor T Cell Therapy in Waldenström Macroglobulinemia: Initial Experience in Two Clinical Trials24
Poster: CT-195 Predictive Value of ST2, REG3a, and MAGIC Algorithm in Haploidentical Transplantation With Post-Transplant Cyclophosphamide Outcomes23
POSTER: MDS-156 Pyrimethamine Shows Synergy and Efficacy in Combination With Venetoclax in Preclinical Models of Therapy Resistant MDS/AML22
Poster: AML-295: Clinical Characteristics and Outcome of Acute Leukemia in Lebanese Patients: A Retrospective Observational Analysis22
AML-156 Early Deaths in Patients With Newly Diagnosed Acute Promyelocytic Leukemia: A Single-Center Retrospective Study From a General Hospital22
Poster: CT-227 Dual CAR-Engineered NK92 Cells: An Off-the-Shelf Cell Therapy for Cancer22
New Targetable Pathways in Chronic Lymphocytic Leukemia (CLL)21
Poster: TCL-084 Subcutaneous Panniculitis-Like T-Cell Lymphoma With Co-Existing Lupus Panniculitis: A Case Report21
P-213: A matching-adjusted indirect comparison of isatuximab plus carfilzomib and dexamethasone versus daratumumab plus lenalidomide and dexamethasone for relapsed multiple myeloma19
POSTER: AML-132 QuANTUM-First Trial: FLT3–Internal Tandem Duplication (FLT3-ITD)–Specific Measurable Residual Disease (MRD) Clearance Is Associated With Improved Overall Survival (OS)19
MCL-179 TP53 Gene Mutations in Russian Patients With Mantle Cell Lymphoma (MCL)19
MM-125 Adipose Tissue Metabolic Activity in Multiple Myeloma19
POSTER: AML-331 Utility of Echocardiogram in Neutropenic Patients With Gram Positive Bacteremia – A Retrospective Study19
Poster: CT-132 Outcome of Sex-Mismatched Allogeneic Hemopoietic Stem Cell Transplantation from Human Leukocyte Antigen–Identical Sibling Donors in Patients With Hematologic Diseases18
MM-369 Clinical Diversity of Multiple Myeloma Over Time, From First Presentation to Diagnosis, in Kurdistan Region, Iraq18
Poster: MM-474 Minimal Residual Disease Perception and Utilization in Real-World Multiple Myeloma Treatment18
CML-062 Define the Vulnerable - Social Determinants of Health Impact on Hematological Malignancies Affecting Children, Adolescents, and Young Adults: Systematic Review and Meta-Analysis18
Poster: MM-198 Anti-BCMA Therapy in Multiple Myeloma: A Single-Center Experience18
MM-341 Clinical Characteristics and Risk of Progression in Patients With Monoclonal Gammopathy of Uncertain Significance (MGUS): Long-Term Experience in a Single Tertiary Hospital18
POSTER: AML-369 Outpatient-Based Low-intensity Induction With Sorafenib in FLT3-ITD-Mutated Newly Diagnosed Acute Myeloid Leukemia (AML)18
MM-459 Safety and Clinical Activity of Belantamab Mafodotin With Lenalidomide Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): DREAMM-6 Arm-A Interim Analysis17
ABCL-289: Matching-Adjusted Indirect Comparison (MAIC) of Axicabtagene Ciloleucel (Axi-Cel) and Lisocabtagene Maraleucel (Liso-Cel) in Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL) After T17
MM-530 Interventions and Outcomes of Multiple Myeloma Patients Progressing after BCMA-Targeted Chimeric Antigen Receptor (CAR) T-Cell Therapy17
POSTER: ALL-020 Localized and Generalized Lymphadenopathy Referred to 3 Tertiary Pediatric Centers Over 6 Years: The Alarming Signs16
CT-009 Prognostic Role of Lymphocyte to Monocyte Ratio in PTS Treated With CAR-T for Aggressive Lymphoma16
ABCL-269 Secondary Central Nervous System (CNS) Involvement in Diffuse Large B Cell Lymphoma (DLBCL): Ten-Year Outcomes From Mexico's National Cancer Institute15
ABCL-181 Germinal Center Double Hit Diffuse Large B-Cell Lymphoma Refractory to Chemoimmunotherapy: A Case Report15
P-103: Profiling the myeloma cell surface proteome reveals CCR10 as a potential immunotherapeutic target15
Poster: MPN-238 Single-Cell RNA Profiling of Myelofibrosis Patients Reveals Pelabresib-Induced Decrease of Megakaryocytic Progenitors and Normalization of CD4+ T Cells in Peripheral Blood15
POSTER: AML-112 Impact of Consolidation Chemotherapy Intensity Before Allogeneic Hematopoietic Stem Cell Transplantation in Elderly Patients With Acute Myeloid Leukemia15
AML-053 Assessment of Minimal Residual Disease in Patients With Adult Acute Myeloid Leukemia: Single Egyptian Center Experience14
AML-013 Differences in Length of Stay Between De novo Diagnosed and Transferred Patients With Acute Myeloid Leukemia in a Community Hospital14
Is Maintenance Therapy Necessary in AML?14
ALL-113: Pattern, Risk Factors, and Outcome Predictors of Posterior Reversible Encephalopathy Syndrome in Pediatric Cancer Patients14
P-099: Perturbation of CDK7 and super-enhancer driven transcriptional programs synergistically halts multiple myeloma cell proliferation14
P-206: Antibodies to omicron variants are maintained in newly diagnosed MM patients on lenalidomide, cyclophosphamide, bortezomib and dexamethasone (RCyBorD): results from the UK RADAR/Myeloma XV Tria14
ALL-071: A Phase 4 Study to Evaluate Outpatient Blinatumomab in Patients with Minimal/Measurable Residual Disease (MRD) Positivity (+) of B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL)14
Poster: ABCL-523 Immunohistochemical (IHC) Expression of Epigenetic Regulators (EZH-2 and H3K27) as well as Cell Cycle Regulators (P16, P53 and RB) in Patients Diagnosed With Primary Diffuse Large B-C14
Poster: MCL-041: Outcomes for Recurrent Mantle Cell Lymphoma Post-BTK Inhibitor Therapy in Japan: An Administrative Database Study13
Poster: MM-171: Melflufen Plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Exposed or Refractory to Prior Alkylators: A Pooled Analysis of the O-12-M1 and HORIZON Studie13
P-212: Quantifying the average treatment effect of single vs. tandem autologous stem cell transplantation in newly diagnosed multiple myeloma using causal inference13
AML-214: Case Report: A Rare Case Presentation and Detection of Acute Promyelocytic Leukemia13
P-097: A novel anti-BCMA lipid-based nanoparticle for multiple myeloma therapy13
Poster: CML-252: Current Patient Management and Outcomes of Chronic Myeloid Leukemia (CML) in Colombia: On Behalf of ACHO’s RENEHOC Investigators13
P-100: Allosteric HSP70 inhibitors perturb mitochondrial proteostasis and overcome proteasome inhibitor resistance in multiple myeloma13
Poster: IBCL-034: Hairy Cell Leukemia: Single-Center Experience13
AML-396 Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Initial Results of a Novel, Ongoing BPDCN International Registry Program12
Poster: MM-250: Pomalidomide in Relapse / Refractory Patients with Multiple Myeloma: A Newly Adopted Approach in Ukraine12
MDS-370: Treatments and Outcomes for Patients with Myelodysplastic Syndromes (MDS) by Revised International Prognostic Scoring System (IPSS-R) Scores at the Huntsman Cancer Institute (HCI)12
EXABS-147-AML How Do We Overcome Resistance to Venetoclax12
CML-129: OPTIC Primary Analysis: A Dose-Optimization Study of 3 Starting Doses of Ponatinib (PON)12
Poster: MM-078: Characterization of Ocular Adverse Events in Patients Receiving Belantamab Mafodotin (Belamaf) for ≥ 12 Months: Post Hoc Analysis of DREAMM-2 Study in Relapsed/Refractory Multiple Myel12
MDS-556 Comparison of Demographics, Disease Characteristics and Outcomes Between Black and White Patients With Myelodysplastic Syndrome: A Population-Based Study12
EXABS-161-MPN Management of Pre-Fibrotic Primary Myelofibrosis12
P-247: Addressing the knowledge gap to optimize treatment sequencing for patients with relapsed/refractory multiple myeloma12
AML-446 Time to Resolution of Myelosuppression and Associated Hospitalization in Patients With Newly-Diagnosed Acute Myeloid Leukemia (AML) Treated With Ivosidenib (IVO) + Azacitidine (AZA) Compared t12
P-141: Prognostic impact of CD3/CD34 ratio in apheresis collection in multiple myeloma patients undergoing autologous stem cell transplant12
CML-417: ASCEMBL Phase 3 Health-Related Quality of Life (HRQL) Comparison of Asciminib and Bosutinib for Patients with Chronic Myelogenous Leukemia in Chronic Phase (CML-CP), Previously Treated with 212
EXABS-134-ALL Dual CAR T-Cell for ALL12
AML-271 Acute Stroke Secondary to Patent Foramen Ovale (PFO) in Patients With Acute Myeloid Leukemia (AML)12
MM-418: Pegfilgrastim in the Supportive Care of Heavily Pretreated Multiple Myeloma in Pomalidomide-Based Treatment11
Poster: HL-049: Clinical Relevance of NKT Cells and Soluble MIC-A in Hodgkin Lymphoma11
MPN-628 Surpass-ET: Ropeginterferon Alfa-2b (P1101) vs Anagrelide as Second Line Therapy in Essential Thrombocythemia11
Poster: MPN-433: Outcomes of COVID-19 in Hematopoietic Stem Cell Transplant Recipients: A Single-Institution, Observational Study11
MM-542 Patient-Reported Outcomes From the DREAMM-7 Randomized Phase 3 Study Comparing Belantamab Mafodotin (Belamaf), Bortezomib, and Dexamethasone vs Daratumumab Bortezomib, and Dexamethasone in Pati11
Management Challenges in Patients with Treatment-Free Remission of Chronic Myeloid Leukemia11
Demographic Characteristics of Hospitalized Patients With History of Multiple Myeloma in Remission: Insights From National Inpatient Sample 202111
POSTER: ALL-553 Unexplained Increase in Incidence of T-Acute Lymphoblastic Leukemia/Lymphoma in Armenia11
TCL-306 Application of the Proposed Immunohistochemistry Algorithm for the Prognostication of GATA3 and TBX21 Subtypes of Peripheral T-Cell Lymphoma, Not Otherwise Specified11
P-455 Survey of multiple myeloma (MM) patients and healthcare professionals (HCPs) on the relevance of existing health quality-of-life (QoL) questionnaires (QoLQ) to real-world QoL issues of MM patien11
Efficacy and Safety of Regimens Used for the Treatment of POEMS Syndrome- A Systematic Review11
Poster: MPN-110: Exosomes in Polycythemia Vera: “Mini Platelets” With Oncogenic and Thrombogenic Potential11
CT-244 Updated Clinical Progress of IL-10 expressing CD19 CAR-T Cells for Treatment of Relapsed or Refractory B-Cell Hematological Malignancies at Tiny Doses11
Utility of CNS Prophylaxis in Diffuse Large B-Cell Lymphoma Patients – A Single Institution Experience From Pakistan11
Factors Influencing Physician Discretion to Administer CNS Prophylaxis in Diffuse Large B Cell Lymphoma: A Single Institution Retrospective Study11
Poster: HL-444: Autoimmune Lymphoproliferative Syndrome: A Case Presentation11
Subject Index11
Poster: MPN-304: Identification of the Key Genes and Molecular Pathways in Essential Thrombocythemia Associated with JAK2V617F Mutation Using Bioinformatics Approach11
OAB-011: Clonal phylogeny and evolution of critical cytogenetic aberrations in multiple myeloma at single cell level11
CT-423: Neuropsychiatric Disorders in Hospitalized Patients Undergoing Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma11
IBCL-381 Studying the Impact of CD38 Expression on Extracellular Adenosine and Its Connection With the PD1/PDL1 Axis in Mature B-Cell Lymphoma Patients11
MPN-153 A Phase 1b Trial of DISC-0974, an Antihemojuvelin Antibody, in Participants With Myelofibrosis and Anemia11
MM-731 Prognostic Implications of Immune Paralysis in Newly Diagnosed Multiple Myeloma11
ABCL-440 Preliminary Safety and Efficacy Data of Combination Polatuzumab Vedotin Rituximab, Cyclophosphamide Adriamycin, Prednisone (Pola-R-CHP) in Patients With Diffuse Large B-Cell Lymphoma (DLBCL) 10
MPN-307 Systemic AA Amyloidosis as a Complication of Idiopathic Multicentric Castleman's Disease10
CML-674 Molecular Screening of Tyrosine Kinase Inhibitor Resistance in Tunisian Patients With Chronic Myeloid Leukemia10
CT-175 The Impact of Diabetes Mellitus on Hematopoietic Stem Cell Mobilization10
MM-645 Updated OS of Patients With AL Amyloidosis After CAEL-10110
Influence of Heart Failure Upon Incidence Rates of Pneumonia, Acute Respiratory Failure, Sepsis and Septic Shock in Patients With Polycythemia Vera10
Evaluating the Impact of an Electronic Medical Record (EMR) Alert on Appropriate Dosing of Luspatercept in Patients With Lower-Risk Myelodysplastic Syndromes (LR-MDS) in a Community Oncology Network10
Therapeutic Efficacy of Acupuncture Combined With Pharmacology in Bortezomib-Induced Peripheral Neuropathy10
Idecabtagene Vicleucel (Ide-Cel) Versus Standard Regimens (SRs) in Triple-Class–Exposed (TCE) Relapsed and Refractory Multiple Myeloma (RRMM): KarMMa-3 Sub-Analysis of Black Patients10
MM-597 Diarrhea in Multiple Myeloma Autologous Stem Cell Transplant Recipients: Think Beyond Mucositis10
Dose-Adjusted Melphalan Yields Comparable MRD-Negativity to Full-Dose Melphalan in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplant10
Olutasidenib Demonstrates Promising Tolerability and Efficacy in IDH1-Mutated Accelerated/Blast-Phase Myeloproliferative Neoplasms10
CLL-656 Multiplex ligation-dependent probe amplification (MLPA): Utility as a first line screening tool for detection of clinically relevant genomic aberrations in CLL10
Frequency of Practice-Changing Findings Identified by Comprehensive Genomic Profiling in Non-Myeloid Hematologic Malignancies10
Barriers to Receiving Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Insights From a Large-Scale Multicenter Observational Study10
ALL-441 Outcome of Adult Acute Lymphoblastic Leukemia, a Single-Center Experience10
CML-627 Concomitant Acid-Reducing Agents With TKI Increases Time to Achieve Remission in Patients With CML: A Real-World Analysis of a US Claims Database10
Time-Dependent Transfusion Status as an Independent Predictor of Overall Survival: A Post Hoc Analysis of 3 Phase 3 Trials10
Limited Toxicity and Impressive Outcomes of Upfront Flag-Based Induction in Newly Diagnosed Acute Myeloid Leukemia: An Indian Scenario10
P-139 Impact of melphalan staggered dosing prior to autologous hematopoietic cell transplantation for multiple myeloma patients9
POSTER: AML-260 A Metabolically Optimized, Non-Cytotoxic Low-Dose Weekly Decitabine/Venetoclax Regimen in MDS and AML9
POSTER: MPN-498 Addition of Navitoclax to Ruxolitinib for Myelofibrosis Patients With Relapsed/Refractory Disease and Suboptimal Response to Ruxolitinib Monotherapy: REFINE Cohort 1 Dose Escalation an9
CLL-240 Frequency of IKZF3 L162R Mutation in B-Cell Lymphoproliferative Disorders9
P-020: PD1-based chimeric-switch receptor expressing NK cells recover from immune checkpoint inhibition in cancer9
Higher Relapse Rate and Resource Utilization With Ara-C Consolidation Chemotherapy Alone Compared With Hematopoietic Cell Transplantation in First Remission in a Cohort of Younger Adults With Acute My9
Outcomes of Bone Marrow Transplant in ESRD vs Non-ESRD Patients: A Nationwide Analysis9
P-100 Prevalence of monoclonal gammopathies in adult Uruguayan population9
P-001: RNA-sequencing reveals transcriptomic similarity of AL amyloidosis and MGUS aberrant plasma cells along with several potential ALA target candidate genes9
POSTER: TCL-154 STAT3 Mutations are Associated With Differential Treatment Responses to Methotrexate and Cyclophosphamide in T-Large Granular Lymphocyte Leukemia9
P-019: Correlative analysis to define patient profiles associated with manufacturing and clinical endpoints in relapsed/refractory multiple myeloma patients treated with idecabtagene vicleucel (ide-ce9
IBCL-297 Phase 2 Study of Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders (LPD) and EBV-Positive Non-Hodgkin Lymphomas (NHL)9
OAB-056: Early, deep, and durable responses, and low rates of cytokine release syndrome with REGN5458, a BCMAxCD3 bispecific antibody, in a Phase 1/2 study in patients with relapsed/refractory multipl9
POSTER: ABCL-142 Efficacy and Safety of Single-Agent Blinatumomab as Salvage Therapy in Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia (B-ALL): Real-Life Experience9
POSTER: ABCL-222 Diffuse Large Cell Lymphoma of the Uterus Presented With Vaginal Bleeding: A Case Report9
POSTER: HL-603 Hodgkin Lymphoma in Tripoli University Hospital Libya9
Efficacy and Safety of Ciltacabtagene Autoleucel ± Lenalidomide Maintenance in Newly Diagnosed Multiple Myeloma With Suboptimal Response to Frontline Autologous Stem Cell Transplant: CARTITUDE-2 Cohor9
POSTER: TCL-196 Hepatosplenic T-Cell Lymphoma in Adolescents and Young Adults: A Case Report9
POSTER: MPN-628 Surpass-ET: Ropeginterferon Alfa-2b (P1101) vs Anagrelide as Second Line Therapy in Essential Thrombocythemia9
CLL-410 Adherence and Discontinuation Among Medicare Beneficiaries Initiating Venetoclax versus BTKis for Relapsed/Refractory Chronic Lymphocytic Leukemia9
OA-38 Physical activity interventions to improve functional performance in patients with multiple myeloma9
Accessing BTK Inhibitors and Other Novel Therapies for Mantle Cell Lymphoma: Are We All Invited to the Party?9
Association Between Hemoglobin Improvement and Patient-Reported Outcomes in Patients With Myelofibrosis and Anemia: Post Hoc Pooled Analysis of Momelotinib Phase 3 Trials9
POSTER: ABCL-039 Metformin in Combination With the Standard Therapy in Patients With Diffuse Large B-Cell Lymphoma: A Randomized Phase II Clinical Trial9
POSTER: HL-281 Treatment of Relapsed Hodgkin Lymphoma With Pembrolizumab as Monotherapy9
Corrigendum to “OAB-005: Update of safety and efficacy of Isatuximab short-duration fixed-volume infusion plus Bortezomib, Lenalidomide, and Dexamethasone combined therapy for NDMM ineligible/with no 8
AML-194 Second Hematological Malignancies in Survivors of Breast Cancer: An Indian Institutional Analysis8
OA-22 TiMMing: developing an innovative suite of bioinformatic tools to harmonize and track the origin of copy number alterations in the evolutionary history of multiple myeloma8
P-266 Pre-clinical characterization of SAR442257, a CD38xCD28xCD3 trispecific T-cell engager in relapsed/refractory multiple myeloma8
POSTER: MM-638 Role of the Combination of FDG-PET plus Whole Body MRI for Staging Newly Diagnosed and Relapsed/Refractory Multiple Myeloma (MM): A Prospective Trial8
ALL-606 A Comprehensive Retrospective Analysis of Cases from 2020-2022 in Children With Relapsed Acute Leukemia: Temporal Trends and Clinical Characteristics8
Editorial Board8
OA-08 GPRC5D-targeted CAR-T cell therapy in patients with relapsed or refractory multiple myeloma progressing after or refractory to BCMA CAR-T cell therapy: updated eesults from a phase 2 clinical tr8
POSTER: MDS-145 A Successful Treatment of Relapsed/Refractory MDS Patient who is Followed Under Hemodialysis8
POSTER: CT-166 Long-Term Safety With ≥12 Months of Pirtobrutinib in Relapsed/Refractory B-Cell Malignancies8
P-383 A 16-gene signature reflecting tumor microenvironment predicts the risk of multiple myeloma patients treated by bortezomib-based therapies8
P-378 Longitudinal antibody and T-cell kinetics over four doses of COVID-19 vaccination and predictors of poor response in patients with multiple myeloma8
POSTER: MPN-193 Incidence of Blast Phase in Myelofibrosis According to Anemia Severity8
AML-327 Novel Anti–B7-H3 Blocking Antibody Enhances NK Cell–Mediated Cytotoxicity and Improves Outcomes in AML-Bearing Mice8
POSTER: MPN-183 Interferon Treatment Suppresses In Vitro NETosis in Neutrophils Derived from Patients With Myeloproliferative Neoplasms8
P-278 Estimating the size of patients with relapsed/ refractory multiple myeloma treated with 1-3 and 4 or more prior lines of therapy in the United States8
P-200 MAP4K2 inhibition reinforces sensitivity to iberdomide in RAS-mutated MM through a CRBN-independent mechanism8
POSTER: CT-127 Evaluation of Cytomegalovirus Infection/Disease Frequency and Risk Factors Following Allogeneic Stem Cell Transplantation: A Single Center Experience8
Neurolymphomatosis: An Unusual Manifestation of Relapsed/Refractory Lymphoma7
P-361 Genomic and transcriptomic landscape of hyper-APOBEC multiple myeloma7
A Prospective Economic Analysis of Early Outcome Data From the Alliance A041202/ CCTG CLC.2 Randomized Phase III Trial Of Bendamustine-Rituximab Compared With Ibrutinib-Based Regimens in Untreated Old7
Poster: CLL-517 Hypertension as an Adverse Event of Ibrutinib: Does Age Matter?7
Phase 3 BELLWAVE-010: Nemtabrutinib Plus Venetoclax Versus Venetoclax Plus Rituximab (VR) in Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)7
OAB-037: Assessing the prognostic utility of the Mayo 2018 and IMWG 2020 smoldering multiple myeloma risk stratification scores applied post diagnosis7
OA-14 Prospective Functional Bone Disease Evaluation of Newly Diagnosed Multiple Myeloma with Combined Use of (18)F-FDG-PET/CT and Whole-Body Diffusion Weighted Magnetic Resonance7
Monoclonal Insulin Autoimmune Syndrome Successfully Treated With Plasma Cell Directed Therapy7
Diffuse Large B Cell Lymphoma in Patients 80 Years and Older: Worse Survival After Treatment Without Increased Relapse Rates7
MPN-469 Rusfertide (PTG-300) Treatment Interruption Reverses Hematological Gains and Upon Reinitiation, Restoration of Clinical Benefit Observed in Patients With Polycythemia Vera7
P-309 ZnDDC, a novel CELMoD-like agent binding to DDB1-CRBN complex demonstrates significant synergism with BTZ and IMiDs and overcomes IMiDs resistance in myeloma cell lines and primary samples7
SOHO State of the Art Updates and Next Questions | Approach to BCR::ABL1-Like Acute Lymphoblastic Leukemia7
Management of Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS) in a Large US Community Oncology Practice: A Focus on Patient Outcomes Post Erythropoiesis-Stimulating Agent (ESA) Treatment7
MDS-570 NPM1-Mutated Myeloid Neoplasms Irrespective of Blast Count Are Associated With Better Outcomes With Acute Myeloid Leukemia Treatment Approach7
Ixazomib With or Without Rituximab Following Maintenance Autologous Stem Cell Transplant in Mantle Cell Lymphoma: A Single-Center Phase I Trial7
P-067 Long-Term Follow-Up From the Phase 1/2 MajesTEC-1 Trial of Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma7
OAB-050: OCEAN (OP-103): a Phase 3, randomized, global, head-to-head comparison study of Melflufen and Dexamethasone (Dex) versus Pomalidomide (Pom) and Dex in Relapsed Refractory Multiple Myeloma (RR7
Table of Contents7
Epidemiological Profile and Outcomes of Patients Admitted to the Intensive Care Unit at Yeolyan Hematology and Oncology Center: A Retrospective Study7
MM-169: ANCHOR (OP-104): Melflufen Plus Dexamethasone and Bortezomib in Relapsed/Refractory Multiple Myeloma (RRMM)—Optimal Dose, Updated Efficacy and Safety Results7
IBCL-541 A Comprehensive Single-Cell Multi-Omic Analysis to Depict the Biological Heterogeneity of Follicular and Large B-Cell Lymphomas7
Venetoclax and Cobimetinib in Relapsed/Refractory AML: A Phase 1b Trial7
A Phase 2 Study of PNT2258 for Treatment of Relapsed or Refractory B-Cell Malignancies7
Treatment Patterns, Efficacy, and Tolerability of Belantamab Mafodotin in Patients With Relapsed and/or Refractory Multiple Myeloma: A Real-World Analysis6
Association Of -308G/A, -238G/A TNF-α Polymorphisms with Multiple Myeloma Risk and Survival: A Systematic Review and Meta-Analysis6
Poster: MM-451 Treatment Patterns Among Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Receiving Second- and Third-Line Therapy in a Medicare Population6
Treatment Options for Patients With Heavily Pretreated Relapsed and Refractory Multiple Myeloma6
SOHO State of the Art Updates and Next Questions | Approach to Older Adults With Phildadelphia-Chromosome Negative Acute Lymphoblastic Leukemia6
Addition of Anti-thymocyte Globulin in Allogeneic Stem Cell Transplantation With Peripheral Stem Cells From Matched Unrelated Donors Improves Graft-Versus-Host Disease and Relapse Free Survival6
A Multistakeholder Qualitative Analysis of Barriers to Autologous Stem Cell Transplantation for Multiple Myeloma6
Hyperfractionated Cyclophosphamide and Dexamethasone Alone or in Combination with Daratumumab and/or Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma: A Single-Center Retrospec6
OAB-053: Mezigdomide (MEZI; CC-92480) in combination with dexamethasone (DEX) and bortezomib (BORT) or carfilzomib (CFZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM)6
P-138 Real World Single Centre Experience On The Use of Radiotherapy In The Treatment of Patients with Multiple Myeloma6
MDS-304 Disparities in Myelodysplastic Syndromes Mortality Among Older Adults in the United States: A CDC WONDER Database Analysis6
Expert Opinion on Multiple Myeloma Treatment in Brazil in the Bispecific Antibody Era6
ALL-004 Philadelphia Chromosome-Positive T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma: A Rare Case Report6
Evaluation of Clinical Characteristics and Prognostic Factors of Early Progressive Disease (EPD) in Newly Diagnosed Multiple Myeloma Patients: Real-World Data of the Greek Myeloma Study Group6
POSTER: ABCL-612 Real-World Outcomes in Patients With Relapsed or Refractory (r/r) Aggressive Large B-Cell Lymphoma (LBCL) Treated With Chemo-Immunotherapy6
MM-492 Long-term Efficacy and Safety Results From the Phase 1/2 MonumenTAL-1 Study of Talquetamab, a GPRC5D×CD3 Bispecific Antibody, in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)6
The Impact of anti-CD38 Monoclonal Antibodies in Frontline Therapy for Patients with Newly Diagnosed Multiple Myeloma: Real-Life Results from the EMMY Study6
Characterization and Outcomes of Spanish Patients With Relapsed/Refractory Multiple Myeloma Included in the LocoMMotion Study6
Evaluating Response Trends of Chlormethine/Mechlorethamine Gel in Patients With Stage I-IIA Mycosis Fungoides: Analysis of Individual Patient Data From a Randomized Controlled Phase II Study to Facili6
Peripheral Blood Involvement at Staging in Patients With Aggressive Peripheral T-Cell Lymphoma6
Hematological Response to Frontline Treatment in Lower Risk Myelodysplastic Syndromes (LRMDS) is Associated With Better Overall Survival6
Real-World Comparison of Carfilzomib, Lenalidomide, and Dexamethasone Versus Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma: KMM2004 Study6
Safety, Feasibility, and Efficacy of Exercise Interventions for People With Multiple Myeloma: A Systematic Review6
Treatment Pattern, Healthcare Resource Utilization and Symptom Burden Among Patients with Triple Class Exposed Multiple Myeloma: A Population-Based Cohort Study6
A Real-life Turkish Experience of Venetoclax Treatment in High-risk Myelodysplastic Syndrome and Acute Myeloid Leukemia6
POSTER: MCL-155 Pirtobrutinib in Covalent BTK Inhibitor Pre-Treated Mantle Cell Lymphoma: Updated Results and Subgroup Analysis from the Phase 1/2 BRUIN Study With >3 Years Follow-Up from Start of 6
POSTER: ABCL-152 Evaluation of Safety Profile of Rituximab + Lenalidomide Protocol in Frail Elderly Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients6
POSTER: CLL-347 Venetoclax Therapy in Chronic Lymphocytic Leukemia Patients Relapsed After Allogeneic Hematopoietic Stem Cell Transplantation6
Recent Advances in the Use of Chimeric Antigen Receptor–Expressing T-Cell Therapies for Treatment of Multiple Myeloma6
Impact of Facility Type on Survival in Chronic Myelomonocytic Leukemia: A Propensity Score Matched, National Cancer Database Analysis6
Generic Lenalidomide Rivelime Versus Brand-name Revlimid® in the Treatment of Relapsed/Refractory Multiple Myeloma: A Retrospective Single-center Experience on Efficacy, Safety and Survival Outcome6
SOHO State of the Art Updates and Next Questions: BTK inhibitors combined with chemoimmunotherapy in CLL, the best of both worlds?6
P-430 Incidence of primary plasma cell leukemia with the new diagnostic criteria6
Delphi Survey on Measurable Residual Disease in Multiple Myeloma: Prevailing Practices and the Way Forward in India6
Practical Guidance on the Clinical Management of Belantamab Mafodotin for Patients With Relapsed/Refractory Multiple Myeloma: Recommendations From the Middle East and North Africa Expert Panel6
IBCL-080 Single Egyptian Oncology Center Experience in Lymphoplasmacytic Lymphoma (LPL)5
MM-241 Management and Outcomes of Anti-CD38 Refractory Multiple Myeloma: Recycling of Therapies and Impact of PFS on Subsequent Treatments5
ALL-434 Xeroderma Pigmentosum and Acute Lymphoblastic Leukemia: Case Report5
ABCL-370 Real-World Clinical Effectiveness of Loncastuximab Tesirine Monotherapy for the Treatment of Relapsed/Refractory Diffuse Large B-cell Lymphoma Following Chimeric Antigen T-Cell Therapy in the5
Prognostic Value of EASIX Score in Allogeneic Hematopoietic Stem Cell Transplantation5
Acute Myeloid Leukemia and Nonseminomatous Germ Cell Tumor in a Patient With Klinefelter Syndrome5
Olverembatinib (HQP1351) Overcomes Ponatinib and/or Asciminib Resistance in Patients With Heavily Pretreated/Refractory Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome–Positive Acute Lympho5
Is Favorable-Risk AML Always Favorable?5
International Expansion of Modern AML Therapy5
POSTER: MM-244 Efficacy of Bendumustine, Pomalidomide, and Dexamethasone (BPD) Regimen in Relapsed/Refractory Extramedullary Myeloma: A Retrospective Study5
POSTER: MDS-225 The Long-Term Efficacy of Erythropoiesis-Stimulating Agents in Patients With Low-Risk or Intermediate-1-Risk Myelodysplastic Syndrome: Multicenter Real-Life Data5
XS004 Dasatinib (XS004) Improves Variability and Bioavailability in Humans Using Amorphous Solid Dispersion Formulation of Dasatinib With Potential Implications for Its Clinical Use5
Next Questions in Aggressive B-cell Lymphomas5
CLL-020 Tumor-Specific Reactive Oxygen Species Accelerators Improve Chimeric Antigen Receptor T Cell Therapy in B Cell Malignancies5
Low MS4A3 Expression Inhibits Differentiation of HSPCs in Patients With Myelodysplastic Syndromes5
AML-750 Global Burden and Trends in Acute Myeloid Leukemia in the European Union From 1990 to 2021: Insights from the Global Burden of Disease Study, 20215
CML-455 Management Challenges in Patients with Treatment-Free Remission of Chronic Myeloid Leukemia5
AML-284 Feasibility of Outpatient Induction in Adolescent and Adult Acute Patients With Myeloid Leukemia in a High-Volume Centre5
POSTER: MPN-339 Outcomes of Patients With Myelofibrosis and Elevated Peripheral Blood Blasts Treated With Pacritinib on Phase II/III Trials5
CT-114 Infectious Complications in Patients With Hematologic Malignancies Receiving CD19 vs. BCMA Targeted CAR-T Therapy5
POSTER: TCL-473 Role of Microsatellite Instability in the Oncogenesis of Primary Intestinal T-Cell Lymphomas5
POSTER: MDS-345 Nature of Clinical Response and Depth of Molecular Response in Patients With TP53-Mutant Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Treated With Magrolimab With A5
P-093 Solitary plasmacytoma: single institution experience and systematic review and meta-analysis of clinical outcomes5
Bone Marrow Necrosis in APML5
HL-447 Lymphoma Diagnosis Delay: Biopsy Strategy Insights5
TCL-246 Peripheral T-Cell Lymphoma (PTCL) and treatment out-come Single centre retrospective study5
Changes in the Metabolome of Serum and Cerebrospinal Fluid During Intensive Treatment of Acute Lymphoblastic Leukemia in Children5
AML-728 Clinical, Molecular, and Treatment Characteristics of Long-Term Survivors Amongst Older Adults with IDH1/2-Mutated Acute Myeloid Leukemia Treated with IDH Inhibitors5
National Trends in the Utilization of Chimeric Antigen Receptor T-Cell Therapy: The Real-World Story Since Its Approval5
POSTER: HL-113 Pharmacokinetics and Safety of Bendamustine in the BEABOVP Regimen for the Treatment of Pediatric Patients With Hodgkin Lymphoma5
P-119 The role of lenalidomide-dexamethasone therapy in elderly patients with multiple myeloma in clinical practice: comparison with bortezomib-based therapy5
OAB-049: Impact of baseline ocular conditions (BOCs) on belantamab mafodotin (belamaf)–related corneal events in patients (pts) with relapsed or refractory multiple myeloma (RRMM)5
POSTER: ABCL-486 A Focus on Cancer-Related Cachexia and Sarcopenia in Hematologic Malignancies5
0.060341119766235